



BRIEF-China FDA Approves ctas for Beyondspring's Second Global Plinabulin Registrational Trial
7/6/17 8:17 AM

Beyondspring Inc:

* China FDA approves ctas for beyondspring's second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention

* Beyondspring- approved company's clinical trial applications (ctas) to allow initiation of two global phase 2/3 trials for its lead asset, plinabulin

* Beyondspring-Targeting reporting phase 2 efficacy data in 2h 2017, phase 3 interim data in 2018, submitting NDA in 2019 to FDA and CFDA for plinabulin Source text for Eikon: Further company coverage:

<https://www.reuters.com/article/brief-china-fda-approves-ctas-for-beyond-idUSASA09W6K>